Cinchocaine Hydrochloride, Dexamethasone, 1,3-Butylene Glycol

4 trials 2 recruiting SOphthalmology & ENT

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

3 Sponsors

15 Countries

Phase II

Phase I/II

Phase I (FiH)

Phase II: 2 Phase I/II: 1 Phase I (FiH): 1

Indications tested

Chondrosarcoma 1 Rhabdomyosarcoma 1 Hodgkin's disease 1 Hepatoblastoma 1

Sponsors using this IMP

Inhibrx Biosciences Inc. 2 European Organisation For Research And Treatment Of Cancer 1 Merck Sharp & Dohme LLC 1

All trials

4 total

A clinical study of patritumab deruxtecan (HER3-DXd) in children with cancer (MK-9999-01C) Recruiting

2024-518771-66-00 Phase I/II 12 countries Merck Sharp & Dohme LLC
Study of INBRX-109 in Patients with Advanced Solid Tumors, Including Sarcomas. Recruiting

2023-508139-29-00 Phase I (FiH) 4 countries Inhibrx Biosciences Inc.
A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarco… Ended

2024-517528-20-00 Phase II 6 countries Inhibrx Biosciences Inc.
EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study Ended

2023-508478-27-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer

Showing 1–4 of 4 trials

← All drugs A–Z